300347 泰格医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.3599.97210.64316.78717.202
总资产报酬率 ROA (%)1.6407.0897.84013.29212.943
投入资产回报率 ROIC (%)1.9268.2779.11015.26415.416

边际利润分析
销售毛利率 (%)39.69538.57739.63743.55347.435
营业利润率 (%)20.45933.68036.44670.91169.615
息税前利润/营业总收入 (%)20.07032.23534.25766.52372.261
净利润/营业总收入 (%)16.60329.11632.06265.05663.560

收益指标分析
经营活动净收益/利润总额(%)106.06973.53474.60942.76734.769
价值变动净收益/利润总额(%)-4.00827.76524.70157.74664.076
营业外收支净额/利润总额(%)0.4380.0640.115-0.337-0.162

偿债能力分析
流动比率 (X)1.4342.7412.9784.49810.222
速动比率 (X)1.4302.7352.9724.49510.218
资产负债率 (%)20.87517.61117.36313.2090.084
带息债务/全部投入资本 (%)17.35414.35313.7117.7993.430
股东权益/带息债务 (%)462.601578.707604.9151,136.8152,729.354
股东权益/负债合计 (%)327.029402.258410.935577.926978.316
利息保障倍数 (X)-41.840-21.973-15.350-16.03026.198

营运能力分析
应收账款周转天数 (天)69.50855.78646.66544.88588.281
存货周转天数 (天)2.0241.8101.1910.6620.636